Novartis is sending two more of its oncology castoffs to a China biotech.
The pharma giant has out-licensed global rights to two of its cancer drugs — the AKT inhibitors afuresertib and uprosertib — to the Shanghai-based company Laekna. Novartis, in turn, picked them up in its big swap with GSK a few years ago, handing over vaccines in exchange for GSK’s late-stage cancer pipeline and products.
The companies did not disclose the terms.
This isn’t their first deal. Novartis handed over a CYP17 inhibitor (CFG920), an oral androgen inhibitor to treat prostate cancer, in a pact they struck with the Chinese company last year.
Just days ago, Novartis also out-licensed global rights to a cancer drug with a troubling history. Adlai Nortye, based in Hangzhou, picked up their PI3K drug buparlisib — after a group of scientists published a report in The Lancet that concluded the drug’s safety profile “does not support its further development” in breast cancer.
Chinese companies have been scooping up regional and global rights to all the drugs they can lay their hands on. And Novartis evidently likes to facilitate the trend with its own unwanted assets.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 32,400+ biopharma pros who read Endpoints News by email every day.Free Subscription